Abstract: A modified immunocyte: (1) which expresses an exogenous unmodified T cell receptor ?-chain and an exogenous T cell receptor ?-chain on the cell surface thereof; or (2) which contains a polynucleotide encoding a T cell receptor ?-chain and a polynucleotide encoding a T cell receptor ?-chain. Thus, a new tool whereby immunity can be appropriately induced in vivo is provided.

Abstract: Provided is a spray chamber including a sample introduction port portion into which a gas flow containing sample droplets that have been atomized by a nebulizer is introduced, a discharge port portion that discharges at least a part of the gas flow introduced into the sample introduction port portion to the outside, and a flow passage tube portion that has the sample introduction port portion on one end portion thereof and the discharge port portion on the other end portion thereof and serves as a flow passage for the introduced gas flow, wherein the flow passage tube portion includes a first tube portion having the discharge port portion on one end portion thereof and a second tube portion having the sample introduction port portion on one end portion thereof, the spray chamber includes a double tube portion.

Abstract: The present technology is mainly directed to providing a technology that enables smooth setting of sheath liquid. Provided is a fluid control device including at least a support portion that supports a sheath liquid storage unit and a sealed portion that houses the support portion. The support portion is detachable from the sealed portion, and the sealed portion is controlled by pressurization in order to feed sheath liquid stored in the sheath liquid storage unit to a microparticle measurement device.

Abstract: A cell for immunotherapy of the present invention includes a nucleic acid encoding a Wilms tumor 1 gene product or a fragment of the Wilms tumor 1 gene product, wherein the nucleic acid including (i) a region encoding a fragment of the Wilms tumor 1 gene product, the fragment being indicated by positions 194 to 493 of amino acid sequence of SEQ ID NO:1 or by positions corresponding to the positions 194 to 493 of amino acid sequence corresponding to SEQ ID NO:1 and (ii) only one AUG as a functional start codon, connected to a 5? terminal side of the region via 3m (m is 124-192) bases intervening between the AUG as the functional start codon and the 5? terminal side of the region, and a nucleic acid encoding CD1d, wherein the cell has been loaded with a glycolipid recognized by antigen receptor of NKT cell.

Abstract: The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the ?-chain region of the T cell receptor gene rearranged to uniform V?-J? in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the ?-chain region of a T cell receptor (TCR) gene has been rearranged to uniform V?-J?. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease.

Abstract: The present technology is mainly directed to providing a technology that enables smooth setting of sheath liquid. To achieve the object, in the present technology, provided is a fluid control device including at least: a support portion that supports a sheath liquid storage unit; and a sealed portion that houses the support portion, in which the support portion is detachable from the sealed portion, and the sealed portion is controlled by pressurization in order to feed sheath liquid stored in the sheath liquid storage unit to a microparticle measurement device.

Abstract: There is provided a connecting member to be attached to a substrate that includes at least a sample introduction section to introduce a sample, a sheath liquid introduction section to introduce a sheath liquid, and a jetting section to jet droplets, the connecting member including at least: a sample introduction linking section to be linked to the sample introduction section; a sheath liquid introduction linking section to be linked to the sheath liquid introduction section; and a charging electrode section that provides charges to at least part of the droplets. The sample introduction linking section and the sheath liquid introduction linking section are positioned so as to be linked to corresponding positions of the substrate.

Abstract: Provided is a spray chamber including a sample introduction port portion into which a gas flow containing sample droplets that have been atomized by a nebulizer is introduced, a discharge port portion that discharges at least a part of the gas flow introduced into the sample introduction port portion to the outside, and a flow passage tube portion that has the sample introduction port portion on one end portion thereof and the discharge port portion on the other end portion thereof and serves as a flow passage for the introduced gas flow, wherein the flow passage tube portion includes a first tube portion having the discharge port portion on one end portion thereof and a second tube portion having the sample introduction port portion on one end portion thereof, the spray chamber includes a double tube portion.

Abstract: The present invention provides use of KLRG1 as a marker specific to memory invariant NKT cells. Using an antibody that specifically recognizes KLRG1, memory invariant NKT cells can be easily detected or isolated.

Abstract: A cell for immunotherapy of the present invention includes a nucleic acid encoding a Wilms tumor 1 gene product or a fragment of the Wilms tumor 1 gene product, wherein the nucleic acid including (i) a region encoding a fragment of the Wilms tumor 1 gene product, the fragment being indicated by positions 194 to 493 of amino acid sequence of SEQ ID NO:1 or by positions corresponding to the positions 194 to 493 of amino acid sequence corresponding to SEQ ID NO:1 and (ii) only one AUG as a functional start codon, connected to a 5? terminal side of the region via 3m (m is 124-192) bases intervening between the AUG as the functional start codon and the 5? terminal side of the region, and a nucleic acid encoding CD1d, wherein the cell has been loaded with a glycolipid recognized by antigen receptor of NKT cell.

Abstract: A cell for immunotherapy of the present invention includes a nucleic acid encoding a Wilms tumor 1 gene product or a fragment of the Wilms tumor 1 gene product, wherein the nucleic acid including (i) a region encoding a fragment of the Wilms tumor 1 gene product, the fragment being indicated by positions 194 to 493 of amino acid sequence of SEQ ID NO:1 or by positions corresponding to the positions 194 to 493 of amino acid sequence corresponding to SEQ ID NO:1 and (ii) only one AUG as a functional start codon, connected to a 5? terminal side of the region via 3m (m is 124-192) bases intervening between the AUG as the functional start codon and the 5? terminal side of the region, and a nucleic acid encoding CD1d, wherein the cell has been loaded with a glycolipid recognized by antigen receptor of NKT cell.

Abstract: A cell for immunotherapy of the present invention includes a nucleic acid encoding a Wilms tumor 1 gene product or a fragment of the Wilms tumor 1 gene product, wherein the nucleic acid including (i) a region encoding a fragment of the Wilms tumor 1 gene product, the fragment being indicated by positions 194 to 493 of amino acid sequence of SEQ ID NO:1 or by positions corresponding to the positions 194 to 493 of amino acid sequence corresponding to SEQ ID NO:1 and (ii) only one AUG as a functional start codon, connected to a 5? terminal side of the region via 3m (m is 124-192) bases intervening between the AUG as the functional start codon and the 5? terminal side of the region, and a nucleic acid encoding CD1d, wherein the cell has been loaded with a glycolipid recognized by antigen receptor of NKT cell.

Abstract: A modified immunocyte: (1) which expresses an exogenous unmodified T cell receptor ?-chain and an exogenous T cell receptor ?-chain on the cell surface thereof; or (2) which contains a polynucleotide encoding a T cell receptor ?-chain and a polynucleotide encoding a T cell receptor ?-chain. Thus, a new tool whereby immunity can be appropriately induced in vivo is provided.

Abstract: A cell of the present invention contains a nucleic acid construct encoding a WT1 gene product or a fragment of the WT1 gene product. The nucleic acid construct contains (i) a region encoding a desired fragment of the WT1 gene product and (ii) only AUG as a functional start codon. The present invention can provide a cell into which the nucleic acid construct is introduced so that an expression level of a WT1 gene product or a fragment of the WT1 gene product is remarkably enhanced.

Abstract: A cell of the present invention contains a nucleic acid construct encoding a WT1 gene product or a fragment of the WT1 gene product. The nucleic acid construct contains (i) a region encoding a desired fragment of the WT1 gene product and (ii) only AUG as a functional start codon. The present invention can provide a cell into which the nucleic acid construct is introduced so that an expression level of a WT1 gene product or a fragment of the WT1 gene product is remarkably enhanced.

Abstract: The present invention provides use of KLRG1 as a marker specific to memory invariant NKT cells. Using an antibody that specifically recognizes KLRG1, memory invariant NKT cells can be easily detected or isolated.

Abstract: An object is to mix multiple liquids sufficiently and then nebulize the mixed liquids while maintaining the nebulizing efficiency. A nebulizer includes a first inner tube disposed inside an outer tube and having therein a first sample passage through which a first liquid sample flows, a second inner tube disposed inside the outer tube in parallel with the first inner tube and having therein a second sample passage through which a second liquid sample flows, a membranous member disposed with a gap between the membranous member and sample outlets formed at respective ends of the inner tubes. The gap forms mixing space in which a gas passing through a gas passage converts the first and second liquid samples flowing out of the sample outlets into droplets and mixes the droplets and the membranous member has multiple holes through which the mixed liquid samples pass along with the gas.

Abstract: The present invention provides a superior method of functional analysis of NKT cells, which enables function analysis of low frequency NKT cells, is independent of the function of autologous APCs, and can avoid an influence of secondary factors and the like.

Abstract: A nebulizer characterized in being provided with: an inner tube, which is disposed coaxially with an outer tube in which a nebulizing outlet is formed and which, together with the outer tube, forms a gas channel therebetween; a sample channel, which is formed inside the inner tube and through which a liquid sample to be nebulized flows; and a reticular membrane disposed with a gap from the sample outlet that is formed at one end of the inner tube and in which multiple holes, through which liquid sample drops flowing out from the sample outlet pass along with a gas, are formed. Using the nebulizer, the particle size of the nebulized liquid droplets can be made uniformly fine over a broad range of sample liquid flow volumes while retention of sample liquid in the nebulizer is reduced.